Nader Nemr1, Rania Kishk2, Mohamed Mandour3. 1. Department of Endemic and Infectious Diseases, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. 2. Department of Microbiology and Immunology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. rankishk@yahoo.com. 3. Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Abstract
BACKGROUND: Ribavirin (RBV)-induced anemia is one of the major causes of dose reduction and discontinuation of therapy for chronic hepatitis C (CHC) patients. We investigated the role of inosine triphosphate pyrophosphatase (ITPA) single nucleotide polymorphism (SNP) (rs1127354) in predicting RBV-induced anemia and thrombocytopenia among Egyptian patients with CHC genotype 4 infection. METHODS: One hundred and twenty Egyptian patients with CHC genotype 4 who had received standard of care combination therapy were enrolled in this study. Single nucleotide polymorphism at ITPA (rs1127354) was genotyped by real-time detection polymerase chain reaction. RESULTS: Hb levels between CC and non-CC groups were significantly different at weeks 4, 8, and 12. Hemoglobin decline was significantly higher among CC patient than non-CC patients at week 4 and week 8 of treatment. The RBV dose reduction was higher in CC than non-CC group. Platelet decline was significantly lower in CC patients than non-CC patients at baseline, 4, 12 weeks only. CONCLUSION: Rs1127354 ITPA polymorphism was associated with RBV-induced anemia and thrombocytopenia in Egyptian patients with hepatitis C virus genotype 4 infection.
BACKGROUND:Ribavirin (RBV)-induced anemia is one of the major causes of dose reduction and discontinuation of therapy for chronic hepatitis C (CHC) patients. We investigated the role of inosine triphosphate pyrophosphatase (ITPA) single nucleotide polymorphism (SNP) (rs1127354) in predicting RBV-induced anemia and thrombocytopenia among Egyptian patients with CHC genotype 4 infection. METHODS: One hundred and twenty Egyptian patients with CHC genotype 4 who had received standard of care combination therapy were enrolled in this study. Single nucleotide polymorphism at ITPA (rs1127354) was genotyped by real-time detection polymerase chain reaction. RESULTS: Hb levels between CC and non-CC groups were significantly different at weeks 4, 8, and 12. Hemoglobin decline was significantly higher among CC patient than non-CC patients at week 4 and week 8 of treatment. The RBV dose reduction was higher in CC than non-CC group. Platelet decline was significantly lower in CC patients than non-CC patients at baseline, 4, 12 weeks only. CONCLUSION:Rs1127354ITPA polymorphism was associated with RBV-induced anemia and thrombocytopenia in Egyptian patients with hepatitis C virus genotype 4infection.
Entities:
Keywords:
Anemia; Drug induced; Genetic polymorphisms
Authors: Alexandra Doehring; Wolf Peter Hofmann; Christina Schlecker; Stefan Zeuzem; Christoph Sarrazin; Thomas Berg; Tobias Müller; Eva Herrmann; Gerd Geisslinger; Jörn Lötsch Journal: Pharmacogenet Genomics Date: 2011-05 Impact factor: 2.089
Authors: Aya Mostafa; Sylvia M Taylor; Mai el-Daly; Mostafa el-Hoseiny; Iman Bakr; Naglaa Arafa; Valérie Thiers; François Rimlinger; Mohamed Abdel-Hamid; Arnaud Fontanet; Mostafa K Mohamed Journal: Liver Int Date: 2010-02-05 Impact factor: 5.828
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie Journal: Hepatology Date: 2009-03 Impact factor: 17.425
Authors: John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir Journal: N Engl J Med Date: 2009-04-30 Impact factor: 91.245
Authors: Nezam Afdhal; John McHutchison; Robert Brown; Ira Jacobson; Michael Manns; Fred Poordad; Babette Weksler; Rafael Esteban Journal: J Hepatol Date: 2008-03-31 Impact factor: 25.083